In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.
Current options, challenges in developing novel therapies.
A retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.
The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
This article is produced by Roche for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.
Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.
While operating on a patient with chronic uveitis presents some challenges, there are a few pearls that may increase success.
Experts discuss the approach to loading doses in the context nAMD and DME. Kaiser, MD explains that loading doses may not be necessary based on studies like the CAT study, while he highlights the importance of individualized treatment plans tailored to the specific needs of each patient and the nuances of different retinal diseases.
Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.
The approval marks the first new steroid on the ophthalmic market in more than 15 years.
Minimizing clinic visits, maximizing use of imaging modalities are key
The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.
Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
A multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
Easier, more accessible functional studies have been made possible
When we discuss trial participation with patients, we stress that the goal of these studies is to obtain better visual outcomes and ease the treatment burden.
Electronic health records may be the future of practice management.
The European Commission is expected to make a decision about the application before the end of June.
Solar retinopathy is caused by prolonged or high intensity exposure of the fovea centralis to light energy. Suspected cases of solar retinopathy may require urgent referral to an ophthalmologist for diagnosis, and to eliminate treatable causes for central visual disturbance.
In an attempt to halt the progression of dry AMD and geographic atrophy, the use of high-resolution optical coherence tomography becomes pivotal.
Dr Charles Wykoff presents the results of a post hoc microperimetry analysis from the OAKS study demonstrating the effectiveness of pegcetacoplan in preserving visual function.
Closing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.
Physicians should consider hydrodynamic cavitation when performing this procedure.
A panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?
To maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimize clinic visits and maximize the use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximizing safety and patients’ vision outcomes.